talkbio – Page 7

ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy

2 weeks ago talkbio0Tagged Appointments, Biotechnology, CEO, Immunotherapy for cancer, Keren Leshem, Leadership, RNA-LNP, ViVac Pharma

ViVac Pharma; Keren Leshem; CEO appointment; RNA-LNP; cancer immunotherapy; leadership; biotechnology

Oncolytics Biotech Provides Update on Special Meeting of Shareholders

2 weeks ago talkbio0Tagged biotech, Corporate, Government, jurisdiction, Nevada, Oncolytics, rescheduling, shareholders, shutdown, update

Oncolytics Biotech; special meeting; shareholders; rescheduling; government shutdown; jurisdiction change; Nevada; corporate update

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

2 weeks ago talkbio0Tagged 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-3-indacene, Cantor, clinical-stage pharmaceutical, Inhibikase Therapeutics, Jefferies, pre-funded, Pricing, public entity

Inhibikase Therapeutics; public offering; common stock; pre-funded warrants; $100 million; Jefferies; BofA Securities; Cantor; clinical-stage pharmaceutical; pricing

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

2 weeks ago talkbio0Tagged aspects of adverse effects, drug response, Genetic screening method, Glucagon-Like Peptide 1, Machine Learning, Mayo Clinic, MyPhenome, Obesity, personalized care, Precision Medicine, Prediction, Treatment Adherence

GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence

EDAP Receives FDA 510(k) Clearance for Advanced Focal One Robotic HIFU System Enhancements

2 weeks ago talkbio0Tagged algorithm, Clearance, Edap, Malignant neoplasm of prostate, Medical Devices, robotic HIFU, United States Food and Drug Administration

EDAP; FDA 510(k) clearance; Focal One; robotic HIFU; high intensity focused ultrasound; ultrasound imaging; prostate cancer treatment; AI algorithms; medical devices

FDA Approves New Indication and Monthly Dosing for Regeneron’s Eylea HD

2 weeks ago talkbio0Tagged aflibercept, Approved, dosing, Eylea, Hodgkin Disease, Macular retinal edema, monthly, Ophthalmology specialty, Pre-filled Syringe, Regeneron, Retinal Diseases, Retinal Vein Occlusion, United States Food and Drug Administration

FDA approval; Eylea HD; Regeneron; macular edema; retinal vein occlusion; monthly dosing; ophthalmology; aflibercept; retinal diseases; pre-filled syringe

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib in TKI Pre-treated Advanced ROS1-positive NSCLC

2 weeks ago talkbio0Tagged acceptance, ARROS-1 trial, Breakthrough Therapy, Clinical Nurse Specialists, Identifier, New Drug Application, Non-Small Cell Lung Carcinoma, Nuvalent, orphan drug designation, PDUFA, Penetration, pre-treated, Protein-tyrosine kinase inhibitor, ROS1-positive, United States Food and Drug Administration, zidesamtinib

Nuvalent; zidesamtinib; FDA acceptance; New Drug Application (NDA); ROS1-positive NSCLC; tyrosine kinase inhibitor (TKI) pre-treated; ARROS-1 trial; PDUFA date; CNS penetration; breakthrough therapy designation; orphan drug designation

AI Proteins Raises $41.5M Series A to Accelerate AI-Designed De Novo Miniprotein Therapeutics

2 weeks ago talkbio0Tagged AI Proteins, Artificial Intelligence, BioCapital, Biotechnology, de novo miniproteins, Drug Discovery, Religious Missions, Santé Ventures, Series A financing, Synthetic Biology, therapeutic protein

AI Proteins; Series A financing; de novo miniproteins; protein therapeutics; artificial intelligence; drug discovery; Mission BioCapital; Santé Ventures; synthetic biology; biotechnology

GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer

2 weeks ago talkbio0Tagged Biotechnology, engagers, hematologic cancers, Immunotherapy, letrozole, Myeloid Progenitor Cells, Neoplasms, preclinical programs, SmithKline Beecham, Solid Neoplasm, strategic collaboration, upfront

GSK; LTZ Therapeutics; myeloid cell engagers; oncology; hematologic cancers; solid tumors; immunotherapy; strategic collaboration; biotechnology; $50 million upfront; preclinical programs

Profluent Raises $106M to Accelerate Frontier AI Models for Programmable Biology, Backed by Jeff Bezos

2 weeks ago talkbio0Tagged AI biotech, Altimeter Capital, Bezos Expeditions, Biological Factors, Clustered Regularly Interspaced Short Palindromic Repeats, Drug Development, Funding, Jeff, Profluent, Programmable Biology, Protein Atlas, protein design, Synthetic Biology

Profluent; AI biotech; protein design; programmable biology; Jeff Bezos; Altimeter Capital; $106M funding; Bezos Expeditions; CRISPR; biologics; Protein Atlas; synthetic biology; drug development